Design Therapeutics (DSGN) Retained Earnings (2020 - 2026)

Design Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$334.8 million in Q2 2026.

• Retained Earnings for Q2 2026 came in at -$334.8 million, down 26.82% year-over-year; the trailing twelve-month figure through Jun 2026 was -$334.8 million (down 26.82% YoY), and the FY2025 annual result was -$297.0 million, down 30.72% from the prior year.
• Retained Earnings eased to -$334.8 million in Q2 2026, from -$314.6 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$60.7 million in Q1 2022 and troughed at -$334.8 million in Q2 2026.
• A 5-year average of -$196.1 million and a median of -$194.6 million in 2024 frame the typical range for Retained Earnings.
• The widest annual swing landed in 2022, when Retained Earnings tumbled 248.23%; it then retreated 26.82% in 2026.
• A 5-year view of Retained Earnings shows it stood at -$110.8 million in 2022, then slumped by 60.36% to -$177.6 million in 2023, then slipped by 27.92% to -$227.2 million in 2024, then plunged by 30.72% to -$297.0 million in 2025, then decreased by 12.73% to -$334.8 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$334.8 million in Q2 2026, -$314.6 million in Q1 2026, and -$297.0 million in Q4 2025.